Abstract
Purpose To validate a novel mobility test (MOST, MObility Standardized Test) and performance outcomes in real (RL) and virtual (VR) environments to be used for interventional clinical studies in order to characterize vision impairment in rod-cone dystrophies, also known as retinitis pigmentosa (RP).
Design Prospective, interventional, non-invasive, longitudinal study (test-retest).
Participants 89 participants in three experimental phases: 15 non visually impaired (controls) in Phase 1 (average age, 27.4 years; 66% women), 14 participants with RP in Phase 2 (average age, 45.2 years, 36% women), and 60 participants (30 RP; average age, 47.4; 44.6% women; and 30 controls, average age, 47.6 years; 45.4% women) in Phase 3.
Methods We designed a mobility test (MOST) to be used in both VR and RL and ran three experimental studies to (1) validate the difficulty of the mobility courses, (2) determine the optimal number of light levels and training trials, and (3) validate the reproducibility (test-retest), reliability (VR/RL), sensitivity, and construct, and content validity of the test. A comprehensive ophthalmologic examination was performed in all subjects.
Main outcomes measures The primary outcome is the performance score in the mobility test. The secondary outcomes include visual acuity, contrast sensitivity, dark adaptation thresholds, static and kinetic visual field parameters, and ellipsoid zone from optical coherence tomography. Correlation between the performance score in the mobility tests and visual function were assessed.
Results Results revealed that the mobility courses developed exhibited statistically similar difficulty, and that five trials are sufficient to control for the learning effect in a session. MOST is highly reproducible (test-retest intra-class correlations > .98) and reliable (correlation VR/RL = .98). MOST achieved a discrimination between RP participants and controls (accuracy larger than 95% in all conditions) and between early and late stages of the disease (mean accuracy of 82.3%). The performance score is correlated with visual function parameter (.57 to .94).
Conclusion MOST is a tool offering validated mobility test, a controlled learning effect, which demonstrates excellent reproducibility and high agreement between real and virtual conditions, as well as sensitivity and specificity to measure disease progression and therapeutic benefit in IRD.
Competing Interest Statement
The authors CNA, MP, AT, AD, AZ, CC are employees of the company Streetlab.
Funding Statement
The project has received funding from Streetlab, the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 861423 (enTRAIN Vision), the Institut Hospitalo-Universitaire FOReSIGHT Enabling Vision Restoration (IHU FOReSIGHT, ANR-18-IAHU-01) and the French government under the Investments for the Future Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ouest V Ethics Committee in France (CPP 19.01446.190402-MS03; IDRCB: 2019-A00483-54; ClinicalTrials.gov ID: NCT04448860) in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
